CLN 617
Alternative Names: CLN-617Latest Information Update: 18 Nov 2025
At a glance
- Originator Cullinan Oncology
- Developer Cullinan Therapeutics
- Class Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Interleukin 12 replacements; Interleukin 2 replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 06 Nov 2025 Discontinued - Phase-I for Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (Intratumoural)
- 06 Nov 2025 Discontinued - Phase-I for Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy) in USA (Intratumoural)
- 06 Nov 2025 Discontinued - Preclinical for Solid tumours in USA (IV)